Unibest
← Back to patent-cliff list

Naproxen Sodium/Sumatriptan Succinate

Tier C — Watch / trade

Naproxen Sodium/Sumatriptan Succinate

Pernix Therapeutics Llc
Originator
2008
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:5-HT, COXs

Brand:Treximet, Suvexx

Indications (approved):Migraine

Regional status

US
Approved
2008-04-15
EU
-
China
Approved
2025-05-20
Japan
-

Factories producing this API10

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

10 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Sign in to view factories →

Synthetic routes & intermediates1 routes

Originator routes × 0Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 6 · Total yield /
SUMAT-0011709-52-0SUMAT-002118870-42-1SUMAT-00366303-55-7SUMAT-004103628-42-8SUMAT-005103654-21-3SUMAT-006103628-43-9SUMAT-007124-40-3SUMAT-008103628-49-5Sumatriptan103628-46-2API · Naproxen Sodium/Sumatriptan Succinate
CodeCAS No.Intermediate
SUMAT-0011709-52-01-(4-aminophenyl)-N-methylmethanesulfonamide
SUMAT-002118870-42-11-(3-hydrazineylphenyl)-N-methylmethanesulfonamide
SUMAT-00366303-55-72-(phenylthio)acetaldehyde
SUMAT-004103628-42-8(E)-N-methyl-1-(3-(2-(2-(phenylthio)ethylidene)hydrazineyl)phenyl)methanesulfonamide
SUMAT-005103654-21-3N-methyl-1-(3-(phenylthio)-1H-indol-5-yl)methanesulfonamide
SUMAT-006103628-43-91-(1H-indol-5-yl)-N-methylmethanesulfonamide
SUMAT-007124-40-3Availabledimethylamine
SUMAT-008103628-49-5N,N-dimethyl-2-(5-((N-methylsulfamoyl)methyl)-1H-indol-3-yl)-2-oxoacetamide
Sumatriptan103628-46-21-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide

Frequently asked questions

What are the approved indications of Naproxen Sodium/Sumatriptan Succinate?

Approved indications include: Migraine.

When does the Naproxen Sodium/Sumatriptan Succinate patent expire?

No public expiry year is available for Naproxen Sodium/Sumatriptan Succinate yet; this page updates once verified.

How many synthesis routes are recorded for Naproxen Sodium/Sumatriptan Succinate?

1 synthesis routes are recorded; the shortest is 6 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Naproxen Sodium/Sumatriptan Succinate intermediates?

1 intermediate CAS of Naproxen Sodium/Sumatriptan Succinate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Naproxen Sodium/Sumatriptan Succinate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29